Company Overview and News

 
GAM’s bond star feels dollar pain as US$600mil gone

2018-10-10 thestar.com.my
LONDON: Paul McNamara has the kind of track record few bond managers can rival: His emerging markets fund has beaten 95% of peers over the past decade, and he’s ahead of the pack again this year.
MORN GMHLF GMHLY

 
U.S., Europe optimism helps global stock index dodge trade war dread

2018-09-10 reuters
NEW YORK (Reuters) - An index of global stock markets rose on Monday for the first time in eight trading sessions on optimism about policy from Italy to the United States, dodging anxiety about the U.S.-China trade war.
GMHLF GMHLY

 
GAM’s Problems Go Way Beyond Its Ousted Manager - Bloomberg

2018-08-01 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
GMHLF GMHLY

 
UPDATE 1-European shares hold steady as results season steams along

2018-07-31 reuters
LONDON (Reuters) - European shares struggled for direction on Tuesday as stocks were pulled about by earnings updates from oil major BP, big lenders and a host of smaller UK companies.
STAN TVPKF 580001 STAB STAN STAC 2888 SCBFF TPK GMHLF TPRKY GMHLY

 
European shares hold steady as results season steams along

2018-07-31 reuters
LONDON, July 31 (Reuters) - European shares struggled for direction in early trading on Tuesday though earnings updates from oil major BP, big banking stocks and a host of smaller UK companies kept things interesting beneath the surface.
STAN TVPKF 580001 STAB STAN STAC 2888 SCBFF TPK GMHLF TPRKY GMHLY

 
European shares set for second week of gains

2018-07-13 reuters
LONDON (Reuters) - European shares opened higher on Friday, set for a second week of gains as fears of a full-blown trade war were kept in check and optimism about the next season of corporate earnings continued to grow.
GMHLF GMHLY

112
SDPI / Superior Drilling Products, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-14 fintel.io - 2
Superior Drilling Products, Inc. (AMEX:SDPI) has 25 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 6,428,637 shares. Largest shareholders include Lone Star Value Management LLC, FMR LLC / Fidelity, Adirondack Research & Management Inc., GAM Holding AG, Renaissance Technologies LLC, Vanguard Group Inc, Woodstock Corp, Acadian Asset Management Llc, Goldman Sachs Group Inc, and Bridgeway Capital Management Inc.
PRTO GALPW STML GMHLY GS GLSSP GALE GMHLF GALEW JBK GSC TFG SDPI SPDI GSJ GJS

55
ACFC / Atlantic Coast Financial Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-11 fintel.io
Atlantic Coast Financial Corp. (NASDAQ:ACFC) has 64 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 9,478,307 shares. Largest shareholders include FJ Capital Management LLC, PL Capital Advisors, LLC, RMB Capital Management, LLC, Mendon Capital Advisors Corp, Vanguard Group Inc, GAM Holding AG, Gabelli Securities, Inc.
ABCB VBLT ACFC GALPW GALE AFCF GMHLF VBLTF STML GALEW GMHLY

1
Tesla Bonds Are in Free Fall - Bloomberg

2018-03-29 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
DHIL GMHLF GMHLY

1
Tesla bonds down to 86 US cents, start to flash warning signals

2018-03-29 themalaymailonline
The logo of Tesla is seen in Taipei October 7, 2017. — Reuters picNEW YORK, March 29 — Elon Musk’s creditors are suddenly having a serious bout of buyer’s remorse.
DHIL GMHLF GMHLY

12
Julius Baer: Unique Business Profile Isn't Fully Reflected On Valuation

2018-03-13 seekingalpha
It has good growth prospects, strong capitalization and high profitability, which aren’t currently fully reflected in its valuation.
3772 MS GMHLF GMHLY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...